Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR)

Authors

  • S. Gudbjörnsdottir,

    1. Department of Medicine, Sahlgrenska University Hospital, Göteborg University, Göteborg, *Department of Public Health and Caring Sciences, Family Medicine and Clinical Epidemiology and †Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, Uppsala, and ‡Department of Clinical Sciences, Lund University, University Hospital, Malmö, Sweden
    Search for more papers by this author
  • K. Eeg-Olofsson,

    1. Department of Medicine, Sahlgrenska University Hospital, Göteborg University, Göteborg, *Department of Public Health and Caring Sciences, Family Medicine and Clinical Epidemiology and †Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, Uppsala, and ‡Department of Clinical Sciences, Lund University, University Hospital, Malmö, Sweden
    Search for more papers by this author
  • J. Cederholm,

    1. Department of Medicine, Sahlgrenska University Hospital, Göteborg University, Göteborg, *Department of Public Health and Caring Sciences, Family Medicine and Clinical Epidemiology and †Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, Uppsala, and ‡Department of Clinical Sciences, Lund University, University Hospital, Malmö, Sweden
    Search for more papers by this author
  • * B. Zethelius,

    1. Department of Medicine, Sahlgrenska University Hospital, Göteborg University, Göteborg, *Department of Public Health and Caring Sciences, Family Medicine and Clinical Epidemiology and †Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, Uppsala, and ‡Department of Clinical Sciences, Lund University, University Hospital, Malmö, Sweden
    Search for more papers by this author
  • B. Eliasson,

    1. Department of Medicine, Sahlgrenska University Hospital, Göteborg University, Göteborg, *Department of Public Health and Caring Sciences, Family Medicine and Clinical Epidemiology and †Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, Uppsala, and ‡Department of Clinical Sciences, Lund University, University Hospital, Malmö, Sweden
    Search for more papers by this author
  • P. M. Nilsson,

    1. Department of Medicine, Sahlgrenska University Hospital, Göteborg University, Göteborg, *Department of Public Health and Caring Sciences, Family Medicine and Clinical Epidemiology and †Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, Uppsala, and ‡Department of Clinical Sciences, Lund University, University Hospital, Malmö, Sweden
    Search for more papers by this author
  • on behalf of the Swedish National Diabetes Register (NDR)

    1. Department of Medicine, Sahlgrenska University Hospital, Göteborg University, Göteborg, *Department of Public Health and Caring Sciences, Family Medicine and Clinical Epidemiology and †Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, Uppsala, and ‡Department of Clinical Sciences, Lund University, University Hospital, Malmö, Sweden
    Search for more papers by this author

: Peter M. Nilsson, MD, PhD, Department of Clinical Sciences, Lund University, University Hospital, S-205 02 Malmö, Sweden. E-mail: Peter.Nilsson@med.lu.se

Abstract

Aims  Patients with Type 2 diabetes and coronary heart disease (CHD) are infrequently treated to risk factor targets in current guidelines. We aimed to examine risk factor management and control levels in a large sample of patients with Type 2 diabetes with CHD.

Methods  This was an observational study of 1612 patients with first incidence of CHD before 2002, and of 4570 patients with first incidence of CHD before 2005, from the Swedish National Diabetes Register (NDR).

Results  In patients with CHD 1–2 years before follow-up, the achievement of cardiovascular risk factor targets (follow-up 2002/follow-up 2005) was: HbA1c < 7%, 47%/54% (P < 0.01); blood pressure ≤ 130/80 mmHg, 31%/40% (P < 0.001); total cholesterol < 4.5 mmol/l, 47%/60% (P < 0.001); and low-density lipoprotein-cholesterol < 2.5 mmol/l, 49%/65% (P < 0.001). Use of medication: antihypertensives, 90%/94% (P < 0.01); lipid-lowering drugs, 75%/86% (P < 0.001); and aspirin, 85%/89% (P < 0.05). A high prevalence of adverse lifestyle characteristics prevailed (2002/2005): overweight [body mass index (BMI) ≥ 25 kg/m2], 86%/85%; obesity (BMI ≥ 30 kg/m2), 41%/42%; smokers in age group < 65 years, 16–23%/18–19%; as well as waist circumference ≥ 102 cm (men) or ≥ 88 cm (women), 68% in 2005.

Conclusions  Patients with a combination of Type 2 diabetes and CHD showed an increased use of lipid-lowering drugs over time, corresponding to improving blood lipid levels. A discrepancy existed between the prevalent use of antihypertensive drugs and the low proportion reaching blood pressure targets. Regretfully, a high prevalence of adverse lifestyle characteristics prevailed. Evidence-based therapy with professional lifestyle intervention and drugs seems urgent for improved quality of secondary prevention in these patients.

Ancillary